Key Takeaways
- Turnaround gaining traction, but still early: FY23 revenue grew 14% YoY to ₹1,466 crores and EBITDA jumped 63%, driven by a base business reset and cost improvement programs. Management is "very upbeat" about returning to historical performance levels, visible from H2 FY24.
- Vizag is the growth engine, now unlocked: US FDA and European CEP approvals received, supply commenced in Q3, and key customers have committed to qualify the site. Capacity utilization is expected to cross 60% by Q4 FY24, with major revenue contribution starting in the second half.
- Margin recovery story is credible but back-end loaded: Gross margin hit 50.3% in Q4 and is called sustainable for the full year, while EBITDA margin is guided to reach high teens only by Q4 FY24, with a full return to 20% levels taking a combination of FY24 and FY25.
- Balance sheet repair is underway: Net current assets reduced by ₹63 crores, working capital days are targeted to drop from 200+ to 150 by FY24, and gross debt fell by ₹23 crores. Net debt to EBITDA improved from 10+ to 6x, with a further marginal reduction expected in FY24.
- What to watch next quarter: Whether Cuddalore gets a reinspection date from the US FDA, which could unlock polymer-based product sales in H2; the pace of Vizag customer qualifications and validation batch uptake; and any concrete revenue or margin guidance, which management declined to provide on this call.
Vizag Facility: The Growth Catalyst
- Regulatory green light secured: The Vizag site received both US FDA and European CEP approval during FY23, removing the single biggest overhang on Solara's growth story. Supply of APIs commenced from Q3 FY23.
- Customer qualification underway: Key customers have committed to qualify Vizag, a process that will drive capacity utilization higher in H2 FY24. Validation quantities are expected to be picked up by customers as qualifications progress.
- Capacity utilization ramp: Management expects substantial improvement from H2 FY24 onwards, with utilization crossing 60% by Q4 FY24. The site is also being qualified as an additional supply source for Ibuprofen to China, a process to be completed within this financial year.
- Revenue potential undisclosed: Management declined to provide peak revenue estimates for Vizag or plant-wise investment figures, stating they will guide on peak revenue only once customers take validation batches and utilization increases in the second half.
- Backward integration completed: One key backward integration program for an API at Vizag was finished in FY23, and 3 of the 5 new US DMFs filed during the year originated from this site.
Devendra: "We are very upbeat in terms of Solara returning to its historical levels, and you will see this from the second half of this financial year."
Margin & Profitability Trajectory
- Gross margin milestone: Q4 FY23 gross margin reached 50.3%, marking consistent sequential improvement over four quarters. Management attributes this to product mix and the cost improvement program (CIP), with raw material costs remaining broadly stable.
- Sustainability claim: The 50% gross margin level is called sustainable for the year as a whole, though quarter-on-quarter fluctuations are expected due to product mix shifts and second-half supply patterns.
- EBITDA margin path: The company plans to return to historical EBITDA margins of high teens or 20%, but the timeline extends beyond FY24. By Q4 FY24, margins are expected to reach high teens, with the full recovery spanning a combination of FY24 and FY25.
- CIP benefits still to flow: Full realization of cost improvement program work undertaken in FY23 will begin flowing through from Q2 FY24, providing an additional tailwind to margins in the coming quarters.
- Vizag under-recovery fading: Under-recoveries at Vizag reduced during FY23 as capacity utilization improved, and this drag should continue to shrink as volumes ramp through H2 FY24.
Devendra: "We want to get back to our historical levels. So yes, we have plans where we will be at high teens, or we'll be at 20%. But it's going to be a combination of just not FY '24, but it will be also FY '25 because if you look at the year as a whole, when you look at an outgoing second half and more so with the Q4 of FY '24, then we will be in the high teens number."
Balance Sheet & Working Capital
- Working capital reset: Net current assets reduced by ₹63 crores in FY23, driven primarily by inventory reduction and GST. A just-in-time concept has been introduced for procurement and production planning, and working capital days are targeted to drop from 200+ to 150 by FY24.
- Debt reduction underway: Gross debt fell by ₹23 crores in FY23, and net debt to EBITDA improved sharply from over 10x in FY22 to 6x in FY23. Management expects only a marginal reduction, around 10% from the ₹1,000 crore level, in FY24 as funds generated will be balanced between debt paydown and growth allocation.
- Fixed asset turnover focus: The company is aiming to improve its fixed asset turnover ratio, though management declined to share plant-wise investment figures or what an optimal turnover ratio would be for the Vizag facility.
Hariharan: "Actually, the number of days is 200 days plus, and it will come to 150 days by FY '24."
Regulatory & Product Pipeline
- Cuddalore reinspection requested: The company has written to the US FDA requesting reinspection of the Cuddalore facility under GDUFA III guidelines. Management is hopeful for an inspection within this financial year, citing a recent wave of warning letter clearances across the industry as a positive signal.
- Polymer-based opportunity contingent on reclassification: If Cuddalore's regulatory status improves, at least one key polymer-based product could generate meaningful sales in the second half. Management noted Solara is one of only two pure-play API companies with currently approved DMFs selling polymer-based products.
- New product momentum: New product revenues contributed 14% of total sales in FY23, yielding from investments made since Solara's inception. Five new US DMFs were filed during the year, and 12 market extensions were achieved for 15 existing products, including 3 in Q4.
- R&D focus shifting to quality: Management emphasized improving R&D velocity with a focus on quality of filings rather than quantity, noting that new products filed now will see commercialization in 2 to 3 years.
- China Ibuprofen entry: Approval for Ibuprofen supply to China has been received and commercial supplies have commenced from the Pondy facility. Management is assessing the actual market size, which they believe is substantially larger than IMS data suggests, and expects a significant jump in requirements in the next financial year.
Devendra: "In the polymer-based chemistry as a pure-play API company, right? There are only two companies who have current approved DMS and selling polymer-based products and one is Solara."
Strategic Direction Under New Leadership
- CEO appointment: Poorvank Purohit joined as CEO, framing the next phase as the "Solara 3.0 growth journey." The strategy rests on four pillars: growing the existing business, launching new products, executing the CIP plan, and building the CRAMS business, with enhanced Vizag capacity utilization as a cross-cutting priority.
- CRAMS expansion: The company is targeting growth in CRAMS through low molecular weight peptides and material sciences, adding a new capability layer beyond its traditional API business.
- Regulated market focus intact: Regulated markets have historically contributed 70-75% of total sales, and the company maintains a deliberately small presence in semi-regulated markets, emphasizing long-term customer relationships over spot business.
- Guidance withheld: Management declined to provide specific revenue or margin guidance for FY24, citing moving parts including Cuddalore reclassification, new products triggered by customers, and Vizag filings. They indicated a willingness to provide guidance "over the next few quarters" once these variables firm up.
Purohit: "I'm excited to be part of Solara 3.0 growth journey."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin sustainability | 50% level sustainable for the full year, with quarterly fluctuations | FY24 |
| Vizag capacity utilization | Cross 60% utilization | Q4 FY24 |
| Working capital days | Reduce from 200+ days to 150 days | By FY24 |
| Net debt reduction | Marginal reduction, approximately 10% from ₹1,000 crores | FY24 |
| EBITDA margin | Reach high teens percentage | Q4 FY24 |
| EBITDA margin full recovery | Return to historical levels of high teens or 20% | Combination of FY24 and FY25 |
| Cuddalore reinspection | US FDA inspection expected | FY24, if not in first half |
| China Ibuprofen supply from Vizag | Qualify Vizag as additional supply site | FY24 |
| CIP benefit realization | Full flow-through of cost improvement program benefits | From Q2 FY24 |
| Revenue and EBITDA growth | Year-on-year improvement, in similar lines of FY23 or better | FY24 |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue growth | 5% YoY |
| Gross margin | 50.3% |
| EBITDA | ₹51.5 cr |
| FY23 revenue | ₹1,466 cr, growth of 14% YoY |
| FY23 gross margin | 46% |
| FY23 operating EBITDA | ₹226.8 cr, 15.5% margin |
| FY23 reported EBITDA | ₹150.7 cr, growth of 63% over last year |
| New product revenue share | 14% of total sales |
| Market extensions in Q4 | 3 market extensions for 3 existing products |
| Vizag capacity utilization target | More than 60% by Q4 FY24 |
| Net debt to EBITDA | 6% in FY23, down from 10 plus in FY22 |
| Gross debt reduction in FY23 | ₹23 cr |
| Net current assets reduction in FY23 | ₹63 cr |
| Working capital days | 200+ days, expected to reduce to 150 days by FY24 |
| Maintenance capex guidance | ₹70 cr to ₹80 cr for FY24 |
| Regulated market sales share | 70% to 75% historically |